Lobe Sciences Ltd. s pleased to announce it has become an official Enterprise Member of the NFL Alumni Association.
Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company“) is pleased to announce it has become an official Enterprise Member of the NFL Alumni Association.
As an Enterprise Member of The NFL Alumni Association (the “NFLAA“), Lobe is able to engage with those who built the NFLAA brand, and who’s clients and customers readily recognize their charitable work.
Mr. Bart Oates, Esq., three time Superbowl champion and President of the NFLAA, is a member of Company’s Advisory Board, as announced by the Company on March 3, 2021. The Company’s focus on mental health issues includes mild traumatic brain injury and PTSD, which can be prevalent in contact sports.
Philip Young, CEO and Director of Lobe stated, “As an Enterprise Member of the NFL Alumni Association, we look forward to supporting their organization and working with the team and their advisors helping to identify more efficient ways of identifying players at risk of or battling various mental health challenges, traumatic brain injuries, and PTSD.”
“We are privileged to have Lobe join our enterprise program to help us “Care For Our Own”. Their scientific focus on developing therapies and devices to combat mental health diseases is very compelling to our members and we look forward to being a part of their scientific developments,” said Bart Oates Esq., President of the NFL Alumni Association and Member of Lobe’s Advisory Board.
NFLAA is a non-profit organization founded in 1967 that is comprised of former NFL players, coaches, staffers, cheerleaders, spouses, and associate members whose mission is to serve, assist and inform former players and their families. It offers a variety of medical, financial, and social programs to help members lead healthy, productive and connected lives, as well as community initiatives under its “Caring For Kids” programs where player alumni give back to their local communities by raising funds for youth and veteran related charities through 35 regional chapters.
About Lobe Sciences Ltd.
Lobe is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.
For further information please contact:
Lobe Sciences Ltd.
Philip J Young, CEO
Tel: (949) 505-5623
THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.
Disclaimer for Forward Looking Statements
This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact included in this release, including statements regarding the future plans and objectives of the Company, identifying more efficient ways of identifying players at risk of or battling various mental health challenges, traumatic brain injuries, and PTSD and the development of therapies and devices to combat mental health diseases, are forward looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.. Readers are cautioned that assumptions used in the preparation of the forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including changes to the regulatory environment; that the Company’s drug research and development activities may be unsuccessful; that drugs and medical devices produced by, or on behalf of, the Company, may not work in the manner intended or at all, and may subject the Company to product liability or other liability claims; that Company may not be able to attain the Company’s corporate goals and objectives ; and other risk factors detailed in the Company’s continuous disclosure filings from time to time, as available under the Company’s profile at www.sedar.com. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made only as of the date of this news release and the Company does not intend to update any of the included forward-looking statements except as expressly required by applicable Canadian securities laws.